Why BTG plc Trounces Barclays PLC And Carillion plc On Growth

BTG plc (LON: BTG) hits the newswires with Barclays PLC (LON: BARC) and Carillion plc (LON: CLLN), but only one firm attracts Kevin Godbold for its growth potential

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Three shares in the news, but only one delivers on potential for decent growth, in my view.

Cyclical recovery

The newswires have it that troubled banking business Barclays (LSE: BARC) seems set to continue shrinking its investment operations, despite the ousting of the firm’s hatchet-wielding chief executive last week.

That strikes me as a good thing for those invested in Barclays. Investment banking activities can deliver the big bucks when things ‘click’, but when they don’t such highly geared punting can stuff up overall profitability, as we’ve seen lately with the firm.

Since mid 2014, Barclays’ share price crept up around 30%. However, even as the firm posts double-digit growth in earnings I’m still not expecting double-digit valuation multiples. An out and out cyclical firm like this, with recovering profits, doesn’t convince me that it has a growth ‘story’. A thirty percent gain over a year looks attractive. If I held the shares, I think I’d be looking for the exit door.

Slight expectations

Yesterday, Carillion (LSE: CLLN) told us it’s trading in line with expectations. According to City analysts following the firm that means a 1% decline in earnings this year followed by a 4% uplift during 2016.

That’s worrying. Carillion is another cyclical firm, this time operating as a support services company and construction contractor with many public/private partnership projects. If the firm isn’t flying now, when the economic sun is shining, when will it?

Carillion’s share price made good progress over the last few years — sideways! The company sports a tempting-looking 5.2% forward yield, but given the cyclical risks involved, I don’t want it.

I’m sure Carillion does a good job with the services it provides and we are all better off because of the companies that roll up their sleeves to make sure the UK thrives. However, I question whether such firms have utility as long-term investment vehicles. Short term, cyclical enterprises like Carillion can provide us with a decent punt on the up-leg of a macro cycle, but that trade finished as long ago as early 2011 for the current undulation, I reckon. Everything since is just ‘noise’!

Growth (oh yes!)

Specialist healthcare company BTG (LSE: BTG) updated the market today saying the business made a good start to the current financial year with overall trading in line with expectations. The City braces reckon that means the firm is on target to grow earnings 27% and they’ve pencilled in a further 41% uplift for next financial year.

That’s a cracking rate of growth and the firm reports that all its business lines are going well. In particular, the directors have high hopes for a product called Varithena, which the company describes as polidocanol injectable foam. In the US, a controlled launch is underway and BTG expects to take around two years from the first commercial sales in August 2014 to achieve widespread adoption and reordering of Varithena by physicians, and to establish a smooth reimbursement process from the American healthcare insurance sector.

With the directors’ strong growth expectations for the financial year starting in April 2016, Varithena looks like an exciting growth development for BTG shareholders.

Although BTG’s business is difficult to understand and lacks earnings visibility, it’s hard to ignore the growth numbers. In fact, I liked them so much I bought the company (or a tiny little slice of it, at least!).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold owns shares in BTG. The Motley Fool UK has recommended Barclays and BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Warren Buffett owns this FTSE 100 stock. But should I?

Warren Buffett rarely invests in FTSE 100 shares but he does have a position in Diageo. Is it time for…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

After returning 101% in 2024 is this FTSE bank the best share to buy for 2025?

FTSE 100 bank NatWest Group turned out to be the best share to buy at the start of this year.…

Read more »

Investing Articles

Could Helium One be a millionaire-maker penny stock?

Shares of Helium One Global (LON:HE1) have soared 272% so far this year. Should I buy this penny stock while…

Read more »

Investing Articles

Are these 2 unsung FTSE blue-chips the passive income stocks I never knew I wanted?

Harvey Jones says that the FTSE 100 contains fantastic passive income stocks with deceptively modest yields. Here are two he's…

Read more »

A mixed ethnicity couple shopping for food in a supermarket
Investing Articles

Shhhh… These FTSE 250 stocks have quietly more than doubled in 2024

Forget those US tech titans. Our writer takes a closer look at two supposedly 'boring' FTSE 250 stocks that have…

Read more »

Investing Articles

As the Diageo share price flies on a double upgrade is this my last chance to buy it on the cheap?

The Diageo share price has inflicted plenty of pain on Harvey Jones in 2024, but suddenly it's serving up a…

Read more »

Investing Articles

7%+ yields! 3 choices to consider for a Stocks and Shares ISA

Christopher Ruane highlights a trio of FTSE companies each yielding over 7% he thinks investors should consider for a Stocks…

Read more »

Passive income text with pin graph chart on business table
Dividend Shares

How investors might try to turn £10,000 into a chunky passive income

Our writer Ken Hall looks at how the magic of compounding returns might help investors to create a handy second…

Read more »